EGFR and lung cancer: In addition to well-known biomarkers of KRAS and EGFR, new genomic biomarkers, such as somatic mutations in ALK, ERBB2, TP53 have been demonstrated to be associated with lung cancer risk, response or prognosis [20], [21], [22].